The third clinical trial evaluated autologous DC vaccine following paclitaxel chemotherapy, prior to surgery and radiation, in patients with stage II/III HER2- BC in a phase 2 trial (NCT00499083). This evidence concerns the gene ERBB2 and breast cancer.